Dr. Fei Qi joined Legend Capital Healthcare Team in 2014, focusing on biotechnology, medical services, and digital health. Dr. Qi led/participated in investments including Ribo, Immunochina, T-cure, Genskey, Enjoy Dental, Phiskin, Baheal Intelligent Technology, etc.

Dr. Qi holds a Ph. D. degree in cell biology and a bachelor degree in biotechnology from Peking University. Prior to joining Legend Capital, Dr. Qi worked as senior scientist at COFCO and a visiting scholar at University of California, Los Angeles (UCLA).

The core business of Legend Capital is early-stage Venture Capital and expansion-stage Growth Capital investment. Legend Capital is now managing several USD funds and RMB funds with a total AUM RMB 45 Billion, and focuses on innovation and growth enterprises with operations in China or related to China. By 2017, Legend Capital has invested in about 450 companies, nearly 70 are successfully listed on the domestic or overseas capital market; besides, 60+ companies achieved exit through M&A.